ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 18 Jan 2021
Last Updated on 18 Jan 2021
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has not recommended listing metformin extended release on the Standard Drug List (SDL) for treating type 2 diabetes mellitus because of limited clinical need and unfavourable cost-effectiveness compared with metformin immediate release.


Metformin extended release for treating type 2 diabetes mellitus (18 Jan 2021)